CVAC News and Press, CureVac N.V. From 11/16/22

Start Time: 09:00 End Time: 10:01 CureVac N.V. (CVAC) Q3 2022 Earnings Conference Call November 16, 2022, 09:00 AM ET Company Participants Franz-Werner Haas - CEO Pierre Kemula - CFO Ulrike Gnad-Vogt - Interim Chief Development Officer Ronald Plasterk...

Delivering on broad second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK Phase 1 studies in influenza and COVID-19 on track to deliver clinical data in Q1 2023 Strengthening oncology position based on preparations f...

CureVac BV ( NASDAQ: CVAC ) is scheduled to announce Q3 earnings results on Wednesday, November 16th, before market open. The consensus EPS Estimate is -$0.24 and the consensus Revenue Estimate is $19.77M Over the last 3 months, EPS estimates have seen 1 upward revis...

On Friday, German biotech CureVac N.V. ( NASDAQ: CVAC ) announced preliminary data from its Phase 1 study for CV8102, a messenger-RNA-based cancer vaccine undergoing studies as a single agent and in combination with PD1-antibodies. The company said that the data readout gene...

Data confirm CV8102's safety and ability to strongly mobilize the immune system against tumors Final data of complete Phase 1 dose-escalation and expansion study expected in H1 2023 TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 11, 2022 / CureVac N.V. (Nasdaq:CVAC...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 10, 2022 / CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for th...

German biotech BioNTech ( NASDAQ: BNTX ) and U.S. partner Pfizer ( NYSE: PFE ) have filed proceedings in a high court in England seeking judgement that their blockbuster mRNA-technology based COVID-19 vaccine does not infringe on two of CureVac's ( NASDAQ: CVAC ...

CureVac BV press release ( NASDAQ: CVAC ): Q2 Pre-tax loss of €57.6M Revenue of €20.1M (-10.3% Y/Y). Cash position of €573.6 million as of June 30, 2022; decreasing headwind of wind-down costs for first-generation COVID-19 vaccine program ...

CureVac ( NASDAQ: CVAC ) said it started a phase 1 trial of a modified COVID-19 mRNA vaccine CV0501, given as a booster dose to previous COVID-19 vaccination. The company added that CV0501, which is being developed in collaboration with GSK ( NYSE: GSK ), is base...

Delivering on broad 2022 second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK; new candidates in COVID-19 and influenza enter clinical studies Phase 1 initiated for modified COVID-19 vaccine candidate CV0501, targeting Omi...